{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.6","upperLimit":"5.9","value":"1.87"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"TTR is defined as the time from first dosing date to the date of the first confirmed complete response (CR) or partial response (PR), as assessed by the Blinded Independent Review Committee (BIRC). Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","dispersionType":"Full Range","groups":[{"description":"Nivolumab 3 mg/kg was administered as a 60 minute IV infusion Q2W","id":"OG000","title":"Nivolumab 3 mg/kg"}],"paramType":"MEDIAN","populationDescription":"All responders-includes responders who had neither progressed nor initiated subsequent therapy at the time of analysis, and excludes responders censored prior to 12 weeks of the clinical data cutoff date (if this cutoff date is before week 48) or prior to 18 weeks of the clinical data cutoff date (if this cutoff date is after or on week 48)","reportingStatus":"POSTED","timeFrame":"From first dosing date to the date of the first confirmed response (up to approximately 14 months)","title":"Time to Response (TTR)","type":"PRIMARY","unitOfMeasure":"Months"}